Entrada Therapeutics (NASDAQ:TRDA) Releases Earnings Results, Beats Expectations By $0.04 EPS

Entrada Therapeutics (NASDAQ:TRDA) posted its earnings results on Thursday. The company reported ($0.94) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.98) by $0.04, FiscalAI reports. The company had revenue of $0.91 million during the quarter, compared to the consensus estimate of $2.30 million. Entrada Therapeutics had a negative return on equity of 57.61% and a negative net margin of 3,537.73%.

Entrada Therapeutics Trading Down 10.1%

NASDAQ TRDA traded down $0.51 on Thursday, hitting $4.55. 305,203 shares of the company’s stock were exchanged, compared to its average volume of 336,524. The stock has a 50-day moving average of $5.89 and a 200-day moving average of $8.64. Entrada Therapeutics has a 52 week low of $4.11 and a 52 week high of $16.45. The stock has a market cap of $177.18 million, a price-to-earnings ratio of -1.15 and a beta of -0.19.

Insider Transactions at Entrada Therapeutics

In other Entrada Therapeutics news, major shareholder Bioventures 2018 L.P. Mpm sold 192,500 shares of Entrada Therapeutics stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $7.41, for a total value of $1,426,425.00. Following the transaction, the insider owned 3,913,952 shares in the company, valued at $29,002,384.32. The trade was a 4.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Kush Parmar sold 92,444 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $7.00, for a total transaction of $647,108.00. Following the transaction, the director owned 2,691,337 shares of the company’s stock, valued at approximately $18,839,359. This represents a 3.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 693,025 shares of company stock valued at $4,964,321. Corporate insiders own 9.49% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on TRDA. Wall Street Zen downgraded shares of Entrada Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday. HC Wainwright reissued a “neutral” rating on shares of Entrada Therapeutics in a report on Monday, October 19th. Roth Capital restated a “buy” rating and set a $11.00 target price on shares of Entrada Therapeutics in a research report on Wednesday, August 12th. Weiss Ratings cut shares of Entrada Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 16th. Finally, UBS Group reiterated a “neutral” rating on shares of Entrada Therapeutics in a research report on Monday, October 19th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $17.75.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc (NASDAQ:TRDA) is a biotechnology company focused on developing therapeutics designed to enter cells and address diseases caused by abnormal or missing intracellular proteins. The company’s approach is based on its Endosomal Escape Vehicle (EEV) platform, which is intended to deliver therapeutic payloads into target cells while helping them escape the endosome, a cellular compartment that can limit the effectiveness of some treatments.

Entrada is developing EEV-based medicines for serious diseases, particularly genetic and neuromuscular conditions.